| No. of patients | 42 |
| Median age in yr (range) | 38.5 (1.6-62.7) |
| Diagnoses | |
| CML | 10 |
| ALL | 9 |
| AML/myelodysplasia | 8 |
| Solid tumors | 5 |
| Multiple myeloma | 6 |
| Non-Hodgkin's lymphoma | 1 |
| Other | 2 |
| Type of transplant | |
| Allogeneic | 31 |
| Autologous | 10 |
| Syngeneic | 1 |
| Preparative regimen | |
| Cy/TBI | 18 |
| Bu/Cy | 8 |
| Bu/Cy/TBI | 5 |
| Bu/Mel/TT | 7 |
| Total marrow radiation/Bu | 1 |
| ATG/Cy/TBI | 3 |
| HLA match (allogeneic recipients only) | |
| Matched sibling | 12 |
| Mismatched family member | 6 |
| Unrelated donor | 31 |
| GVHD prophylaxis (allogeneic recipients) | |
| Cyclosporine | 2 |
| Cyclosporine/MTX or TMTX | 25 |
| Cyclosporine + prednisone | 3 |
| FK506 + MTX 1 |
| No. of patients | 42 |
| Median age in yr (range) | 38.5 (1.6-62.7) |
| Diagnoses | |
| CML | 10 |
| ALL | 9 |
| AML/myelodysplasia | 8 |
| Solid tumors | 5 |
| Multiple myeloma | 6 |
| Non-Hodgkin's lymphoma | 1 |
| Other | 2 |
| Type of transplant | |
| Allogeneic | 31 |
| Autologous | 10 |
| Syngeneic | 1 |
| Preparative regimen | |
| Cy/TBI | 18 |
| Bu/Cy | 8 |
| Bu/Cy/TBI | 5 |
| Bu/Mel/TT | 7 |
| Total marrow radiation/Bu | 1 |
| ATG/Cy/TBI | 3 |
| HLA match (allogeneic recipients only) | |
| Matched sibling | 12 |
| Mismatched family member | 6 |
| Unrelated donor | 31 |
| GVHD prophylaxis (allogeneic recipients) | |
| Cyclosporine | 2 |
| Cyclosporine/MTX or TMTX | 25 |
| Cyclosporine + prednisone | 3 |
| FK506 + MTX 1 |
Abbreviations: Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; Mel, melphalan; TT, thiotepa; ATG, antithymocyte globulin; MTX, methotrexate; TMTX, trimetrexate; CML, chronic myeloid leukemia; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia.